SEC Tracker
Get the app

Artiva Biotherapeutics ARTV

Artiva Biotherapeutics announces Wind Down costs

Artiva Biotherapeutics (ARTV) filed an 8-K/A with the SEC on Nov 9, 2026, 4:07 pm ET. Source: the filing on SEC EDGAR.

Item 2.05 Exit or restructuring costs

Form
8-K/A
Filed
Importance
Notable
  1. $10 million to $15 million in contract termination costs
  2. $17 million to $20 million in workforce reduction costs
  3. Workforce reduction expected in Q1 2027

Written from the 8-K/A on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Artiva Biotherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.